Podcasts about Keynote

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

In this Podcast Extra episode, John Kempf delivers his keynote address from "The Quality Edge: Market Differentiation Through Regenerative Wine Growing," an event hosted by Grgich Hills Estate in Rutherford, California. Speaking to an audience of professional wine growers, John explores how regenerative agriculture is becoming the ultimate differentiator in a crowded global market. He details how focusing on soil biology and plant physiology not only restores ecosystems but drives the production of wines with distinct character and superior quality that today's consumers demand. Key Topics Discussed: Why wine grapes are one of the few crops where microbiome integrity translates directly to harvest quality and financial return. The "Rhizophagy Cycle" and how plant roots absorb entire microbial cells to extract nutrients. Recent discoveries that microbes act as "truckers", transporting lipids and nutrients into plants before returning to the soil. The concept of "quorum sensing" and how microbial communities behave as a superorganism once they reach a critical threshold of diversity. How trees and plants demonstrate intelligence and support one another through fungal networks, including the "Mother Tree" concept. The three major suppressors of soil biology: bare soil, high-salt fertilizers, and synthetic fungicides. Why synthetic fungicides are often more damaging to soil structure and biology than tillage or herbicides. Introduction to Pinion, a new biocontrol product from AEA that influences plant redox environments and activates immune pathways. The critical role of Manganese and Boron as bottlenecks for photosynthesis and sugar translocation. Additional ResourcesTo learn more about Pinion, please visit: https://advancingecoag.com/product/pinion/ About John Kempf John Kempf is the founder of Advancing Eco Agriculture (AEA). A top expert in biological and regenerative farming, John founded AEA in 2006 to help fellow farmers by providing the education, tools, and strategies that will have a global effect on the food supply and those who grow it. Through intense study and the knowledge gleaned from many industry leaders, John is building a comprehensive systems-based approach to plant nutrition – a system solidly based on the sciences of plant physiology, mineral nutrition, and soil microbiology. Support For This Show & Helping You Grow Since 2006, AEA has been on a mission to help growers become more resilient, efficient, and profitable with regenerative agriculture.  AEA works directly with growers to apply its unique line of liquid mineral crop nutrition products and biological inoculants. Informed by cutting-edge plant and soil data-gathering techniques, AEA's science-based programs empower farm operations to meet the crop quality markers that matter the most. AEA has created real and lasting change on millions of acres with its products and data-driven services by working hand-in-hand with growers to produce healthier soil, stronger crops, and higher profits. Beyond working on the ground with growers, AEA leads in regenerative agriculture media and education, producing and distributing the popular and highly-regarded Regenerative Agriculture Podcast, inspiring webinars, and other educational content that serve as go-to resources for growers worldwide. Learn more about AEA's regenerative programs and products: https://www.advancingecoag.com

Apple is shaking up creative workflows with its Creator Studio subscription, bundling pro apps and unleashing new AI-powered features that could change how students, artists, and power users work. But does this shift mark a new era or just another subscription headache? • Creator Studio pricing, student and educator discounts, and included apps • Paid features vs. existing free and owned apps clarified • Subscriptions vs. 1-time purchases • Family Sharing option extends Creator Studio to up to five users • Student and educator benefits • Freeform's role, delayed features, and real-world usefulness • Pages, Numbers, and Keynote gain premium templates and content hub • Keynote to auto-generate presentations from outlines using AI • Final Cut Pro: new AI tools, transcript search, beat detection, montage maker • Logic Pro: AI-assisted music creation, chord ID, royalty-free packs, smart search • Motion, Compressor, and Mainstage overview and macOS exclusivity • Pixelmator and Photomator transition concerns addressed • Creator Studio lowers pro app entry barriers but keeps 1-time purchases • News: Setapp's EU iOS app store to shut down due to business model issues • Feedback: switching from iPad Pro to iPad Mini experience • Shortcuts Corner: shortcut for HAM radio contact location logging • App Caps: Spigen Classic LS case and CANSHN magnetic case Hosts: Mikah Sargent and Rosemary Orchard Contact iOS Today at iOSToday@twit.tv. Download or subscribe to iOS Today at https://twit.tv/shows/ios-today Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

Apple is shaking up creative workflows with its Creator Studio subscription, bundling pro apps and unleashing new AI-powered features that could change how students, artists, and power users work. But does this shift mark a new era or just another subscription headache? • Creator Studio pricing, student and educator discounts, and included apps • Paid features vs. existing free and owned apps clarified • Subscriptions vs. 1-time purchases • Family Sharing option extends Creator Studio to up to five users • Student and educator benefits • Freeform's role, delayed features, and real-world usefulness • Pages, Numbers, and Keynote gain premium templates and content hub • Keynote to auto-generate presentations from outlines using AI • Final Cut Pro: new AI tools, transcript search, beat detection, montage maker • Logic Pro: AI-assisted music creation, chord ID, royalty-free packs, smart search • Motion, Compressor, and Mainstage overview and macOS exclusivity • Pixelmator and Photomator transition concerns addressed • Creator Studio lowers pro app entry barriers but keeps 1-time purchases • News: Setapp's EU iOS app store to shut down due to business model issues • Feedback: switching from iPad Pro to iPad Mini experience • Shortcuts Corner: shortcut for HAM radio contact location logging • App Caps: Spigen Classic LS case and CANSHN magnetic case Hosts: Mikah Sargent and Rosemary Orchard Contact iOS Today at iOSToday@twit.tv. Download or subscribe to iOS Today at https://twit.tv/shows/ios-today Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

You start with Quick Tips that tighten up your daily Apple workflow fast. You learn how CarPlay scrubbing actually works while driving, how Siri can jump forward or back in precise time chunks, and why Apple's vision for Siri, Gemini, and personal intelligence matters more than the hype suggests. You unlock practical wins like copying Voice Memos transcripts, using Continuity for clipboard magic across devices, mastering iPhone copy and paste gestures, and understanding when dragging photos quietly converts them to JPEGs. Along the way, you revisit Apple Newton roots, discover why tools like Yoink still matter, and pick up slick tricks for prepping images in Messages and pausing voice recordings mid-thought. Then you move into real-world problem solving. You figure out how to record a selfie video on iPhone while reading a script without breaking your flow, why Sign in With Apple is still worth using, and how to monitor drive health without guessing. You finally get clarity on weird Trash behavior, stop your mouse from waking your Mac, and understand why green bubble RCS and SMS sometimes fail on macOS. The episode wraps with a discussion about Apple Creator Studio tools like Logic Pro, Final Cut Pro, Pixelmator Pro, Compressor, MainStage, and premium content across Apple's productivity apps. Listen to sharpen your instincts so when it counts, you Don't Get Caught. 00:00:00 Mac Geek Gab 1125 for Monday, January 19th, 2026 January 19th: Brew a Potion Day MGG Monthly Giveaway – Enter to win a copy of Ecamm Live or Carbon Copy Cloner 7! The MGG Merch Store is Live! MGG's CES 2026 Sponsors: BusyCal (with code MACGEEK10)! Eero Ecamm for Zoom integration MacPaw CCC Backup Quick Tips 00:00:01 Chris-QT-CarPlay lets you scrub while driving 00:04:01 QT-Use Siri to skip forwards and backwards in specific time increments 00:06:18 The future of Siri, Gemini, and Personal Intelligence 00:14:33 QT-See and copy transcripts from Voice Memos 00:15:44 QT-Continuity works for Clipboard Too 00:18:21 iPhone Copy/Paste Gestures 00:21:55 Doug-QT-Dragging photos on iPhone converts them to JPEG Copying/Pasting on the Apple Newton Yoink 00:27:01 Jeff-QT-Dragging an image into Messages preps it to send 00:28:15 Pete-QT-Pause Voice Recording on iOS 00:29:54 How do I record a selfie video on my iPhone while being able to read a script? Teleprompter for Video for iPhone Also Teleprompter is free with in app purchases 00:34:43 GW-QT-Don’t forget about Sign in With Apple Sponsors 00:38:50 SPONSOR: Tempo. For a limited time, Tempo is offering my listeners SIXTY PERCENT OFF your first box! Go to TempoMeals.com/MGG. 00:40:22 SPONSOR: Stamps.com. Try Stamps dot com risk-free for sixty days at stamps.com and use code mgg! Sixty days gives you plenty of time to see exactly how much time and money you’re saving on every shipment. 00:41:42 SPONSOR: CleanMyMac. Get Tidy Today! Try 7 days free and use our code MACGEEK for 20% off at clnmy.com/MACGEEK Your Questions Answered and Tips Shared! 00:43:12 Andy-What should I use to monitor drive health? Disk Drill DriveDx Techtool Pro for repairing APFS volumes 00:48:52 Gary-Why Sometime Trash? Why Sometimes NO Trash? 00:59:37 Andrew-How can I keep my mouse from waking up my Mac? 01:03:25 Caleb-Why can’t I send green bubble RCS/SMS messages from my Mac? Cool Stuff Found 01:07:19 CSF? Apple Creator Studio Logic Pro Pixelmator Pro Final Cut Pro Compressor MainStage Premium content for Pages, Numbers, Keynote, Freeform, Motion and more 01:18:31 MGG 1125 Outtro MGG Monthly Giveaway Bandwidth Provided by CacheFly MGG's CES 2026 Sponsors Pilot Pete's Aviation Podcast: So There I Was (for Aviation Enthusiasts) The Debut Film Podcast – Adam's new podcast! Dave's Business Brain (for Entrepreneurs) and Gig Gab (for Working Musicians) Podcasts MGG Merch is Available! Mac Geek Gab YouTube Page Mac Geek Gab Live Calendar This Week's MGG Premium Contributors MGG Apple Podcasts Reviews feedback@macgeekgab.com 224-888-GEEK Active MGG Sponsors and Coupon Codes List BackBeat Media Podcast Network

Jan 3rd I did a keynote talk at Momentum 2026 conference, where I covered the 5 pillars of optimal human performance. This is a high energy talk covering sleep archetecture with the 6/3/1/30 protocol, nutrition from the ground up, movement and fitness design, building a performance environement and stress. Enjoy. 

On this year's first episode of The MacRumors Show, we take a look at CES 2026, Apple Creator Studio, and the confirmation that Google Gemini will power the next-generation version of Siri. Following ‌CES 2026‌, we talk through this year's tech showcase, which saw major announcements related to robotics, AI, and display technology, as well as plenty of new Apple accessories. We discuss some of our favorite products highlighted at the event, such as Strada and the Clicks Power Keyboard.Apple this week announced a new bundle called “Apple Creator Studio" that offers access to six creative apps, as well as exclusive AI features and content, as part of a single subscription. In the U.S., pricing is set at $12.99 per month or $129 per year. Six apps are included with the subscription: Final Cut Pro on the Mac and iPad Logic Pro on the Mac and ‌iPad‌ Pixelmator Pro on the Mac and ‌iPad‌ Motion on the Mac Compressor on the Mac MainStage on the Mac For college students, Apple Creator Studio costs $2.99 per month or $29.99 per year. If you set up Family Sharing, you can share an Apple Creator Studio subscription with up to five other family members with a linked Apple Account for free. Pixelmator Pro was previously only available on the Mac, but it is now coming to the iPad. Apple Creator Studio subscribers will receive access to exclusive AI features and premium content across not only the Final Cut Pro and Pixelmator Pro apps, but also the iWork apps Numbers, Pages, and Keynote, and the Freeform app later this year. Apple Creator Studio will be available through the App Store starting on Wednesday, January 28. Final Cut Pro, Logic Pro, Pixelmator Pro, Motion, Compressor, and MainStage will each remain available for one-time purchase, and free versions of the Numbers, Pages, Keynote, and Freeform apps will continue to exist, but only Apple Creator Studio subscribers will receive access to some of the premium new AI features and content.In other news, Apple this week released a statement confirming that Google Gemini will power the next-generation version of ‌Siri‌ that is slated to launch later this year, as was widely rumored. After a considerable delay, the new capabilities will deliver better understanding of a user's personal context, on-screen awareness, and deeper per-app controls.Apple's decision to lean on Google's artificial intelligence technology should result in the revamped ‌Siri‌ being more capable and advanced than it otherwise would have been, as Gemini's large language model is significantly larger than Apple's own model. Apple and Google added that Gemini will help power not only a more personalized version of Siri, but a range of future Apple Intelligence features.The next-generation version of ‌Siri‌ is expected to be introduced with iOS 26.4, which will likely be officially released to the public in March or April.Save more than fifty percent on term life insurance at https://www.selectquote.com/macrumors and get started today!

Most founders know they should be visible, but very few understand what it actually takes to show up with clarity, confidence, and conviction—without performing or posturing.In this episode of Founder Talk, Alex Sheridan sits down with Donna Marie Post, keynote curator, speaker coach, wardrobe consultant, and founder of TEDx Arlington Heights. Donna Marie works with leaders, founders, and executives to help them craft ideas worth sharing—and deliver them in a way that creates real impact, not surface-level inspiration. Together, they unpack what visibility really demands of founders, why fear of being seen often masquerades as fear of public speaking, and how ego quietly derails otherwise strong ideas.Key TakeawaysWhy fear of visibility is often fear of being seen, not fear of speakingHow founders accidentally dilute their message by copying what already existsThe difference between performing confidence and embodying convictionWhy service-driven messaging builds more trust than self-promotionHow imposter syndrome shows up at higher levels of leadershipWhat makes a keynote, video, or message truly memorableWhy play, curiosity, and presence matter more than polishQ&A-Style Takeaways with Timestamps00:00:00 – Introduction00:07:23 – Why would a founder choose to build under an existing brand like TEDx instead of creating their own event?Donna Marie explains how attaching to an established global brand creates instant credibility, trust, and momentum.00:11:39 – What hidden leadership challenges come with running a volunteer-driven organization?The conversation highlights how leading unpaid, mission-driven teams forces founders to develop clarity, emotional intelligence, and purpose-driven leadership.00:17:00 – How does imposter syndrome show up after you've already “made it”?Donna Marie shares how imposter syndrome often intensifies at higher levels of visibility.00:18:00 – Why are successful founders still afraid to get on camera or speak publicly?Alex reframes visibility as service, not self-promotion.00:29:06 – Is fear of public speaking really about speaking at all?The episode reframes the fear as discomfort with being seen, judged, and perceived.00:31:26 – What does it actually take to move through fear instead of trying to eliminate it?Donna Marie explains why surrender—not confidence hacks—is what allows founders to stay present.00:49:04 – What's the biggest mistake founders make when creating content or keynotes?They discuss how copying language, frameworks, and “safe” messaging leads to forgettable ideas and erodes trust.00:54:01 – Why does over-professionalism hurt connection with an audience?The conversation introduces the idea of “death by professionalism”.00:58:12 – How can founders use AI without losing their voice or originality? AI can act as a mirror that helps founders clarify what isn't aligned—strengthening their authentic perspective.This episode is especially relevant for founders navigating visibility, leadership presence, or the pressure to “show up” as an authority. Watch the full conversation to hear the nuance behind these ideas—and subscribe for more grounded, no-fluff founder interviews on Founder Talk.

BOOK: In Covid's Wake: How Our Politics Failed Us In In Covid's Wake: How Our Politics Failed Us, authors Frances Lee and Stephen Macedo examine the unprecedented mobilization of emergency powers during the COVID-19 pandemic, when nearly half the world's population was under quarantine by April 2020. Their eye-opening analysis questions how institutions responded to the crisis, why pre-existing pandemic plans were ignored, and how COVID-19 policies often benefited the "laptop class" while leaving essential workers exposed, revealing how scientific discourse became increasingly politicized as reasonable dissent was marginalized.In this Keynote from Cornell's College of Arts & Sciences, Princeton Professor Frances Lee will speak about her best-selling book, offering a comprehensive — and candid — political assessment of how U.S. institutions fared during this historic global crisis. This timely discussion will explore the successes and failures of America's pandemic response and its implications for future crisis management.  Follow eCornell on YouTube, Facebook, Instagram, LinkedIn, TikTok, and X.

Benjamin and Chance discuss the implications for Siri and the wider Apple ecosystem now that the Gemini deal is officially signed, and guess when we'll start seeing the first new features ship. Also, they weigh up the appeal of the new Apple Creator Studio bundle, and Chance got to watch basketball courtside through his Vision Pro. And in Happy Hour Plus, the duo discuss the dependability of iCloud as a backup of your data, and what other backup strategies they recommend to use. Join now and save 26% on annual plans with code HAPPY26. Sponsored by Copilot Money: The personal finance app to make your money yours. Until January 20, get 26% off your first year at try.copilot.money/9to5mac. Sponsored by Stamps.com: Send from your computer or phone 24/7. Try Stamps.com risk-free for sixty days with code happyhour. Sponsored by 1Password: Take the first step to better security by securing your team's credentials. Find out more at 1password.com/happyhour and start securing every login. Hosts Chance Miller @ChanceHMiller on Twitter @ChanceHMiller on Instagram @ChanceHMiller on Threads Benjamin Mayo @bzamayo on Twitter @bzamayo@mastodon.social @bzamayo on Threads Subscribe, Rate, and Review Apple Podcasts Overcast Spotify 9to5Mac Happy Hour Plus Subscribe to 9to5Mac Happy Hour Plus! Support Benjamin and Chance directly with Happy Hour Plus! 9to5Mac Happy Hour Plus includes:  Ad-free versions of every episode  Pre- and post-show content Bonus episodes Join for $5 per month or $50 a year at 9to5mac.com/join. Join now and save 26% on annual plans with code HAPPY26 until February 1. Feedback Submit #Ask9to5Mac questions on Twitter, Mastodon, or Threads Email us feedback and questions to happyhour@9to5mac.com Links Apple confirms Google's Gemini will power new Siri features Apple to fine-tune Gemini independently, no Google branding on Siri, more Apple will pay billions for Gemini after OpenAI declined Will Apple-Google AI deal impact user privacy? Here's what Apple says Eddy Cue touts ‘record-breaking year' for Apple services, including TV, Music, more Apple debuts 'Apple Creator Studio' subscription, here's what you get Pages, Numbers, Keynote, and Freeform becoming freemium apps Apple announces Pixelmator Pro is coming to iPad Apple Creator Studio Icon History What it's like to watch an NBA game courtside in Apple Vision Pro Apple gift card safety questioned after terrifying account lockout

This week's second special episode is Scott's opening keynote from Be Better At Being Bad 2026 at Hedonism II Resort: The Freedom Mandate: The Ethical Case for Relational Freedom.Scott unpacks Wild Love Theory's seven-word thesis, “Maximum relational happiness requires maximum relational freedom,” and asks the question that can feel both inspiring and terrifying: If your partner's happiness matters to you… do you owe them freedom?From there, he draws a crucial line between true boundaries (inward-facing choices for self-protection) and what most couples call “boundaries” but are actually imposed limits designed to manage fear. He explains why rules can be necessary early on, but only as scaffolding: temporary supports meant to loosen as trust, regulation, and repair become load-bearing.The talk ends with a raw, personal story from Scott and April's relationship: the moment Scott kissed April goodbye as she got ready for a date with no rules, and what that taught him about control, courage, and what it means to build a relational cathedral two free people can actually live inside.Next week we'll release our full recap of BBBB 2026. If this keynote brings up questions or reflections, email Scott anytime at naughtygymonline@gmail.com.Website:www.NaughtyGym.comUpcoming Events:1. Wild Love Theory Retreat -- https://www.naughtygym.com/wild-love-theory-retreat2. Barcelona Adventure Trip -- https://www.naughtygym.com/barcelona-20263. El Salvador Retreat -- https://www.naughtygym.com/naughty-gym-el-salvador

Can AI really reorder how business works - not just automate tasks, but redefine entire markets? In this episode, Frazer Anderson sits down with two leading thinkers - Conor Twomey and Ray Wang. They discuss: How AI exponentials fundamentally rewrite productivity and what that means for founders, enterprises, and investors competing with legacy incumbents. The evolving state of enterprise AI adoption - from prototypes to production‑scale agent workflows that transform business outcomes and unit economics. Why scaling enterprise AI depends less on model quality and more on your data foundation, internal coordination, and ability to operationalize agents across real workflows. — Conor Twomey is an accomplished executive with over 15 years of experience in addressing complex data challenges for leading global corporations. He is currently an AI Co-Founder at Stealth Startup. Conor is the former Head of AI Strategy at KX, a pioneer in real-time data analytics and decision intelligence. Under his leadership, KX successfully transitioned from a time-series database company to the Enterprise AI platform of choice for large-scale AI implementations. Before this role, Conor managed a 400-person organization encompassing Presales, Professional Services, Support, Managed Services, and Customer Success Management. Renowned for his insights on data and AI, Conor is a sought-after speaker and contributor on frontier technology topics, including Data, Analytics, Machine Learning, AI, and Generative AI. — Ray Wang, a tech luminary, is the Co-Founder & Chairman of Constellation Research, a Bestselling Author, and a Keynote speaker. Renowned for his insights into digital transformation and enterprise technology, Ray's expertise stems from influential roles at Altimeter Research and Forrester Research. His bestselling books, including "Disrupting Digital Business" and "Everybody Wants to Rule the World," delve deep into the impact of digital technologies on business models.

Apple has a package deal for creative software including Final Cut Pro, Keynote, and Pages, in an effort to compete with Adobe Creative Cloud. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this opening keynote from Naughty Gym's Be Better At Being Bad Takeover at Hedonism Resort, Coach April invites you into a deeply honest exploration of desire, identity, and self trust. Through personal stories and lived experience, she challenges the roles, labels, and expectations that shape what we think we should want and asks a more powerful question: what do you actually want? This talk is about unlearning goodness, releasing approval seeking, and reconnecting with the quiet wisdom of the body. It's an invitation to stop performing the life you were taught to live and start listening to the truth that's been waiting underneath it all. This is not about having it all figured out. It's about coming home to yourself and beginning again, on purpose. Website: www.NaughtyGym.com Upcoming Events: 1. Wild Love Theory Retreat -- https://www.naughtygym.com/wild-love-theory-retreat 2. Barcelona Adventure Trip -- https://www.naughtygym.com/barcelona-2026 3. El Salvador Retreat -- https://www.naughtygym.com/naughty-gym-el-salvador

Jessica Donington, MD, and Christine Bestvina, MD, join host Erin Gillaspie, MD, to unpack key lung cancer advances from ESMO 2025, including adjuvant ALK inhibition (ALINA, ELEVATE), perioperative immunotherapy (KEYNOTE-671), and the expanding neoadjuvant space in borderline resectable disease.

Listen to a recap of the top stories of the day from 9to5Mac. 9to5Mac Daily is available on iTunes and Apple's Podcasts app, Stitcher, TuneIn, Google Play, or through our dedicated RSS feed for Overcast and other podcast players. Sponsored by Stuff: Stuff helps you get everything out of your head and into a simple, elegant system—closing open loops and reducing mental stress. Use code 9TO5 at checkout for 50% off your first year. New episodes of 9to5Mac Daily are recorded every weekday. Subscribe to our podcast in Apple Podcast or your favorite podcast player to guarantee new episodes are delivered as soon as they're available. Stories discussed in this episode: Will Apple-Google AI deal impact user privacy? Here's what Apple says iOS 26.3 beta 2 hints at upcoming end-to-end encryption for RCS Apple debuts ‘Apple Creator Studio' subscription, here's what you get Apple announces Pixelmator Pro is coming to iPad Pages, Numbers, Keynote, and Freeform becoming freemium apps Listen & Subscribe: Apple Podcasts Overcast RSS Spotify TuneIn Google Podcasts Subscribe to support Chance directly with 9to5Mac Daily Plus and unlock: Ad-free versions of every episode Bonus content Catch up on 9to5Mac Daily episodes! Don't miss out on our other daily podcasts: Quick Charge 9to5Toys Daily Share your thoughts! Drop us a line at happyhour@9to5mac.com. You can also rate us in Apple Podcasts or recommend us in Overcast to help more people discover the show.

Back-from-break headlines cover winter weather conditions, rockstars and leadership at STN EXPO East, updates from the U.S. Environmental Protection Agency, and what impact recent developments in Venezuela could have on the school bus industry. Keynote speaker and best-selling author Jim Knight, who rubbed shoulders with musicians and celebrities during his tenure with Hard Rock International, discusses building a student transportation brand and improving workplace culture. He will present a keynote and Transportation Director training at STN EXPO East in Charlotte, North Carolina this March. Read all our latest news. Episode sponsor: Transfinder.

Want to Start or Grow a Successful Business? Schedule a FREE 13-Point Assessment with Clay Clark Today At: www.ThrivetimeShow.com   Join Clay Clark's Thrivetime Show Business Workshop!!! Learn Branding, Marketing, SEO, Sales, Workflow Design, Accounting & More. **Request Tickets & See Testimonials At: www.ThrivetimeShow.com  **Request Tickets Via Text At (918) 851-0102   See the Thousands of Success Stories and Millionaires That Clay Clark Has Helped to Produce HERE: https://www.thrivetimeshow.com/testimonials/ Download A Millionaire's Guide to Become Sustainably Rich: A Step-by-Step Guide to Become a Successful Money-Generating and Time-Freedom Creating Business HERE: www.ThrivetimeShow.com/Millionaire   See Thousands of Case Studies Today HERE: www.thrivetimeshow.com/does-it-work/  

Can AI improve your quality of life, not just your productivity?   Keynote speaker Amy Jo Martin explores leadership, AI, and human-centered decision-making.  In this solo episode of the Why Not Now? Podcast, Amy shares early field notes from The Reinvention Experiment, a year-long AI self-experiment exploring vitality, clarity, and what it means to live well and lead effectively in an AI-driven world.   Rather than biohacking or performance optimization, Amy introduces the concept of Quantified Soul, combining hard data like sleep tracking, screen time, biometrics, and wearable data with qualitative inputs including journaling, emotional regulation, gratitude, and relationship check-ins.   Key insights include why "a wobble is data, not drama," how journaling with AI can help regulate the nervous system, and why cognitive load often creates more stress than conflict. Amy also breaks down what she's tracking, the AI prompts she uses daily, and how AI can surface blind spots instead of reinforcing existing narratives.   This episode is intentionally raw and unfinished. You're stepping inside the experiment itself and exploring how AI can support better decision-making, reflection, and long-term fulfillment, not just efficiency.   Amy Jo Martin speaks globally on Humanizing AI, Leadership, Decision-Making, and the Future of Work.  Learn more about keynote topics and availability: https://amyjomartin.com/speaking   Get Amy Jo's newsletter: amyjomartin.com/newsletter
 Watch Amy Jo's Speaking Reel: amyjomartin.com/speaking
 Learn more about Renegade: www.renegade.global/
 Follow Amy Jo…
 Instagram: www.instagram.com/amyjomartin/
 X/Twitter: twitter.com/amyjomartin
 Facebook: www.facebook.com/AmyJoMartin/
 YouTube: www.youtube.com/@AmyJoMartinRenegade
 Why Not Now? Instagram: www.instagram.com/whynotnow/
 Buy Amy Jo's book: amyjomartin.com/book
 Follow Renegade Global: www.instagram.com/renegade_global    

For this episode, Dr. Joe Tafur and Natasha Pentin spoke with Tania de Jong AM, an award-winning social entrepreneur, acclaimed soprano, inspirational speaker and storyteller, creative alchemist, philanthropist and spiritual journey woman. Many of our listeners wanted to learn more about the power of music for healing and the neuroscience of singing together, so in this episode we explore all of that – as well as the rescheduling of psychedelic medicines in Australia, building an ecosystem for accessible and affordable treatment, how therapists become authorized prescribers, and what other countries can learn from this pioneering approach.Tania was appointed a Member of the Order of Australia, and has also been named in the 100 Women of Influence, 100 Most Influential Entrepreneurs in Australia, and 100 Most Influential People in Psychedelics globally. She has developed six businesses and four charities including: Creative Universe, Creativity Australia and the With One Voice program, Creative Innovation Global, Mind Medicine Australia, Umbrella Foundation and Driftwood The Musical, Pot-Pourri and The Song Room. Thanks for listening! If you'd like to support the nonprofit Modern Spirit and our podcast, you can make a donation HERE. There, you can also access links to Dr. Tafur's newsletter and Patreon. More information about Tania:  Her website & Instagram  Her TED talk - How Singing Together Changes The Brain Learn more about Mind Medicine Australia, Pot-Pourri group and Creativity Australia's With One Voice programs (alleviating loneliness, depression and social isolation).  A Keynote video  Listen to her music here (you can hear Circle of Life 30 mins in and Don't Go Back to Sleep at 33 mins - both from The Breezes at Dawn album). Her Spotify playlist for psychedelics  NEW SINGLE: Walking Each Other Home – Inspired by Ram Dass and Our Shared Human Journey. Access full music video or download for free. Timestamps: (00:00) Introduction to Tania de Jong AM(03:25) Tania's Journey into Psychedelics(06:52) Life-Changing Experiences with Psilocybin(08:19) Founding a Charity for Psychedelic Treatments(09:34) Australia Becomes First Country in the World to Reschedule Psilocybin and MDMA(12:10) Communicating Through Skepticism & Taboo(17:59) Training Therapists for Psychedelic Therapy(22:32) How Psychedelic Treatments Currently Work in Australia(25:27) Costs, Funding, Insurance & Access to Treatments (29:21) The Power of Music in Healing(33:44) Ethics and Overmedication in the Modern World(37:29) Healing Together Through Voice, Community & Reciprocity(41:07) The Neuroscience of Singing Together(43:49) Music and Visionary Experiences(47:23) Integrating Music into Healing Practices (51:07) Upcoming Projects and Final Thoughts

The Squeaky Wheel. Bridge Bump Pub Grab. Zynberg?

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

On this episode of the Hayek Program Podcast, Mario Small delivers a keynote lecture at the 2024 Markets & Society conference on financial institutions and racial inequality—using payday lenders as a lens to understand how place and institutional context shape economic life.Small begins with a deceptively simple question: how often is it easier to reach a payday lender than a traditional bank—and does that vary by neighborhood racial composition? He shows that racial gaps in access and attitudes persist even after accounting for socioeconomic differences, and argues that proximity, convenience, and institutional experience help shape preferences, even as most Americans hold negative views of payday lenders.Together, these insights offer a nuanced account of how neighborhood context and institutional behavior interact to reproduce inequality, challenging simple explanations rooted in individual choice and highlighting the importance of lived experience in economic decision-making.Dr. Mario L. Small is Quetelet Professor of Social Science at Columbia University. A University of Bremen Excellence Chair, and an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, the American Academy of Political and Social Sciences, and the Sociological Research Association, Small has published award-winning articles and books on urban inequality, personal networks, and the relationship between qualitative and quantitative methods. His books include Villa Victoria: The Transformation of Social Capital in a Boston Barrio, Unanticipated Gains: Origins of Network Inequality in Everyday Life -- both of which received the C. Wright Mills Award for Best Book -- and Someone To Talk To: How Networks Matter in Practice, which received the James Coleman Best Book Award among other honors.**This episode was recorded October 12, 2024.If you like the show, please subscribe, leave a 5-star review, and tell others about the show! We're available on Apple Podcasts, Spotify, Amazon Music, and wherever you get your podcasts.Check out our other podcast from the Hayek Program! Virtual Sentiments is a podcast in which political theorist Kristen Collins interviews scholars and practitioners grappling with pressing problems in political economy with an eye to the past. Subscribe today!Follow the Hayek Program on Twitter: @HayekProgram

Most firms are still fighting for attention the same way they always have. Meanwhile, discovery is changing fast. Recorded live at PIMCON 2025, this special bonus episode features Chris Dreyer's keynote on the non-negotiables for showing up in search as AI-driven discovery accelerates. Drawing on data from working with more than 200 PI firms, Chris breaks down where visibility actually comes from today—and which fundamentals will decide who gets discovered and who gets left behind. You'll learn: Where AI tools actually pull their information from when ranking lawyers Why Google, Reddit, and Wikipedia now matter more than most firms realize Which legal directories are referenced most often—and which ones aren't Why reviews, content, and links still determine discovery across every platform What firms need to do now as AI overviews and search behavior continue to shift If you like what you hear, hit subscribe. We do this every week. Buy tickets for PIMCON 2026: pimcon.orgGet Social! Personal Injury Mastermind (PIM) powered by Rankings.io is on Instagram | YouTube | TikTok

Change remains the only constant in hospitality, but today's accelerated pace brings unprecedented opportunities to innovate and differentiate your brand. Technology and AI are enabling streamlined operations and personalized guest experiences that drive loyalty and revenue.Consumer behavior shifts like mindful drinking trends, for example, present deep challenges but can also open new revenue streams for savvy operators who know how to pivot. In this Keynote from Cornell's Nolan School of Hotel Administration, we'll explore successful adaptation strategies that can strengthen your business model and broaden your appeal.Join industry leader Peter Karpinski from Pyramid Global Hospitality and Cornell Senior Lecturer and industry veteran Douglass Miller as they discuss how to survive and thrive in this rebounding market as well as what it takes to gain competitive advantage. They'll also share storytelling techniques for reaching today's experience-hungry consumers.Check out Doug's Beer Essentials Cornell Certificate Program herePyramid Global Hospitality  Follow eCornell on YouTube, Facebook, Instagram, LinkedIn, TikTok, and X.

Perimenopause and menopause can feel like a time of massive change.  Because it IS! And with physical and hormonal changes comes the need for a big upgrade to your exercise and wellness routine. That's why I've brought expert Brian Keane onto the podcast to offer insight on optimally evolving your healthy habits to move with you through this wonderful season of life.  We dive into why restriction or an all-or-nothing approach to exercise can completely backfire in perimenopause and what to focus on instead for strength, energy, and longevity.  Brian also shares the most overlooked opportunities for building sustainable, effective wellness habits in midlife.  If you're ready to lean into this powerful season of life with confidence (and less frustration), this episode is for you! Tune in now.  Brian Keane Brian Keane is a 3x bestselling author, certified strength and conditioning coach, sports nutritionist, and the host of the top podcast, The Brian Keane Podcast. Brian has been a featured speaker at prominent wellness events, and was a Keynote speaker at Google HQ for their 2018 wellness event. Outside of business, he's completed some of the world's most grueling feats, including six consecutive marathons through the Sahara Desert, a 230km trek through the Arctic, and multiple ultra-marathons—highlighted by a 100-mile race through the desert in Nevada. IN THIS EPISODE Why your nutrition and exercise routine must change in midlife  Adjusting your mindset for optimal strength and resilience  Top strength and exercise recommendations for midlife women  The benefit of consistency in fitness vs. an all-or-nothing approach  Some of the most overlooked opportunities for healthier fitness and nutrition habits in midlife Non-negotiable force-multipliers for a healthier you Why sleep is the best thing you can do for your health Debunking certain health and wellness myths seen in the media  QUOTES“You don't judge a tree for its leaves falling off in autumn– don't judge yourself for moving into a new season of life.” “We can sometimes fail to see that the small things make a massive difference, whereas in other areas of life, you will do small things with your partner, with your son, with your daughter, and you know that they compound– putting them to bed, reading the story, having that time, you know that these small little things add up to building up that relationship and making it stronger. But with exercise, it's very easy to take an all or nothing approach.” RESOURCES MENTIONED My Newest Book: The Perimenopause Revolution  https://peri-revolution.com/ Connect with Brian HERE! Brian on TikTok Brian on Instagram Brian on Facebook Brian Keane Fitness on YouTube  RELATED EPISODES  #546: How to Stay Lean, Energized and Strong By Working With Your Physiology, Not Against It with Dr. Stacy Sims 684: The 5-Minute Workout That Boosts Metabolism, Energy & Reverses Aging with Ulrich Dempfle 657: How to Prevent, Manage, and Even Reverse Osteoporosis Naturally: The Hormone-Bone Health Connection Every Woman Needs to Know with Dr. Doug Lucas  #616: Jump-Start Your Metabolism and Put Your Body into a Thermogenic Fat-Burning State with Stu Schaefer

HAPPY NEW YEAR!! Thank you so much for yet another amazing year in Insurance Town!! This weeks episode is a little different, No Guest. This week i am releasing one of my keynote presentations from a conference I spoke at this year, IIANC, thank you to my friend AUBE KNIGHT and his amazing staff in North Carolina for hosting me and helping me to learn and grow in a big way!! THAT CONFERENCE HAD a major impact on my life personally and Professionally!! This is my keynote, OUT OF SERVICE, I hope you enjoy! SponsorsSmart ChoiceCanopy Connect MAV

View this video at https://macmost.com/using-freeform-as-a-presentation-tool.html. You can use the Freeform app that comes with your Mac as a presentation tool that has a unique zooming style distinctly different than Keynote. You can create all of your content on a single Freeform board and then define scenes to use as slides.

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study. We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients. Key topics covered in this episode included: • Overview of the Keynote-905/EV-303 study and its significance • Comparison with previous studies like the NIAGARA trial • Discussion on the side effects of EV Pembro and management strategies • The role of ctDNA in guiding post-operative therapy • Future directions in bladder cancer research and upcoming trials Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology! #BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC

In today's episode, the discussion features Christof Vulsteke, MD, PhD, head of the Integrated Cancer Center Ghent in Belgium, who provided clinical and regulatory insight into the KEYNOTE-905 study (NCT03924895) and the November 2025 FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC). In this exclusive interview, Dr Vulsteke outlined the scientific rationale and study design of KEYNOTE-905, reviewed the key efficacy and safety findings observed with the enfortumab vedotin/pembrolizumab combination, and discussed how the safety profile of this combination aligns with prior experience in bladder cancer. He also contextualized the significance of this FDA approval in addressing a longstanding unmet need for cisplatin-ineligible patients and highlighted remaining gaps in care, including global access, patient selection, and future research directions aimed at improving outcomes in this challenging-to-treat population.

Eric Meyer, Founder and Executive Director for Generation Atomic, addresses the crowd at the 2025 Growth Summit as the morning keynote. Listen in as Eric explains the advancements in nuclear energy and discusses what is on the horizon nuclear power generation in the United States.

Aji and Sally join forces to discuss the different ways they utilise active models in their workflows. Aji describes a new system for working with active models they've been using recently, Sally recalls a project where active models could have saved her a lot of time, before putting their heads together to think of new creative ways to utilise rails' tools toolset to build other active models. — Discover more of The Magic of Rails through Eileen Uchitelle's Keynote (https://www.youtube.com/watch?v=TgNb2_LSMMo), or check out the GitHub repo (https://github.com/thoughtbot/administrate) mentioned in this episode. Thanks to our sponsors for this episode Judoscale - Autoscale the Right Way (https://judoscale.com/bikeshed) (check the link for your free gift!), and Scout Monitoring (https://www.scoutapm.com/). Your hosts for this episode have been thoughtbot's own Sally Hall (https://www.linkedin.com/in/sallyannahall) and Aji Slater (https://www.linkedin.com/in/doodlingdev/). If you would like to support the show, head over to our GitHub page (https://github.com/sponsors/thoughtbot), or check out our website (https://bikeshed.thoughtbot.com). Got a question or comment about the show? Why not write to our hosts: hosts@bikeshed.fm This has been a thoughtbot (https://thoughtbot.com/) podcast. Stay up to date by following us on social media - YouTube (https://www.youtube.com/@thoughtbot/streams) - LinkedIn (https://www.linkedin.com/company/150727/) - Mastodon (https://thoughtbot.social/@thoughtbot) - BlueSky (https://bsky.app/profile/thoughtbot.com) © 2025 thoughtbot, inc.

Today, on Notable Leaders' Radio, I am going to share the wisdom from this year's guests. I noticed a theme in the messages that the guests shared. They each spoke from their perspectives on the importance of failure and being human as key elements of their success. Not the lack of them, but rather embracing them. In today's episode, we discuss: Remember that you succeed because you're human, not despite it. Give yourself permission to feel, learn, and be imperfect, self‑trust and humanity fuel far better leadership than white‑knuckled control ever will Commit fully to the action and loosen your grip on the outcome. When you focus on aligned effort instead of rigid results, "failure" turns into feedback, experimentation feels safer, and it becomes much easier to stay in motion. Let your intuition come to work. The quirks, nonlinear career steps, and hard‑won stories you're tempted to hide are often exactly what make your leadership memorable, trustworthy, and uniquely valuable. Build flexible "blueprints" instead of rigid scripts. Map out where you're headed, but hold the plan lightly so you can adjust to new information, opportunities, or constraints without losing your sense of direction. In seasons of disruption, ask: Who am I becoming? Instead of freezing or bracing for impact, use job changes, industry shifts, or personal upheavals as prompts to align more closely with the kind of leader and human you want to be. Normalize vulnerability as part of your leadership toolkit. Naming your struggles, asking for help, or saying "I don't know yet" builds trust, strengthens teams, and creates room for others to be honest about what they need to thrive. Belinda's Bio:  Belinda is a sought-after Leadership Advisor, Coach, Consultant, and Keynote speaker, and a leading authority in guiding global executives, professionals, and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with organizations such as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, Portland Trail Blazers, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has conducted over 120 interviews with top-level executives and business leaders, who share their personal journeys to success, revealing the truth about what it took to achieve their success on her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President and Global Director of Creative Management at Grey Advertising, managing over 500 people worldwide. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace.   Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/  Surround yourself with experienced mentors. From public speaking training to business skills, Jourdan emphasizes that growing into leadership is a journey supported by those who have already walked the path.

In this special season finale, we're closing out Season 10 with a fun, reflective conversation inspired by a few of our favorite things. As we take a short pause from the podcast, we share some of our favorite strengths-based questions, hands-on tools, and learning approaches that actually stick. This episode is full of ideas you can use right away, whether you're a coach, leader, or strengths enthusiast.

Transform your challenges into strength and exceptional achievement! Embrace the power of resilience to elevate yourperformance.

Bitcoin isn't just an asset—according to Michael Saylor, it's the foundation of a new global financial system. In this keynote, Saylor breaks down how bitcoin becomes digital capital, how digital credit outperforms every bond market on earth, and why digital money will reshape banking. He also shares Strategy's blueprint for turning bitcoin holdings into perpetual yield instruments.#Bitcoin #MichaelSaylor #Strategy⭐️⚔: SIGN UP WITH DUELBITS TODAY FOR A CHANCE TO WIN UP TO 2 BTC:

Learn more about The 2030 Project: A Cornell Climate Initiative https://climate.cornell.edu/Cornell College of Engineering https://www.engineering.cornell.edu/Cornell College of Agriculture and Life Sciences https://cals.cornell.edu/As concerns about climate change intensify, researchers are exploring the potential for large-scale human intervention in the Earth's climate system – a set of strategies collectively known as geoengineering. Some of these strategies, called sunlight reflection methods, involve techniques like adding aerosols to the stratosphere to reflect a small portion of solar radiation back into space. Though still in the early stages of research, sunlight reflection and other geoengineering ideas raise complex scientific, ethical, and political questions.In this Keynote, three experts from Cornell University delve into what geoengineering is and what it isn't. Clarifying the science, the panel will separate fact from fiction and discuss why a cautious, transparent, and interdisciplinary approach is essential.This conversation is part of The 2030 Project: A Cornell Climate Initiative, administered by the Cornell Atkinson Center for Sustainability. Follow eCornell on YouTube, Facebook, Instagram, LinkedIn, TikTok, and X.

Keynote event featuring Dustin Goetz, Acting Chief Information Officer for the US Immigration and Customs Enforcement (ICE). The event covers crucial topics such as modernization strategies, asset inventory, data standardization, and cybersecurity integration. Goetz emphasizes the importance of seamless cybersecurity integration, automating tier one security operations, and preparing for evolving threats, including AI and post-quantum computing. The episode underscores ICE's commitment to modernization and collaboration with industry to enhance cybersecurity capabilities.Subscribe on your favorite podcast platform to never miss an episode! For more from ACT-IAC, follow us on LinkedIn or visit http://www.actiac.org.Learn more about membership at https://www.actiac.org/join.Donate to ACT-IAC at https://actiac.org/donate. Intro/Outro Music: See a Brighter Day/Gloria TellsCourtesy of Epidemic Sound(Episodes 1-159: Intro/Outro Music: Focal Point/Young CommunityCourtesy of Epidemic Sound)

In our December episode, Dr. Tiffany Cudjoe-John explored with us the physical and mental health benefits of expressing gratitude. Of course, some of us may need a little encouragement in learning to recognize and appreciate the good things in life. So, for our Key Note episode, we asked Dr. Cudjoe-John to share a simple meditation you can use to help foster a thankful mindset. We hope this moment of reflection inspires you to begin your own gratitude journey.  The Takeaway   We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Visit the Healthy Minds section of our Healthy Living Resource Center for additional information and resources: www.1199SEIUBenefits.org/healthyminds/.  Connect with a therapist online through Teladoc: www.Teladoc.com  or (800) TELADOC (835-2362).  Find a mental health therapist through the Benefit Funds' Provider Directory: www.1199SEIUBenefits.org/find-a-provider. For additional support, call our Wellness Member Assistance Program: (646) 473-6900. Contact our partners at the National Alliance on Mental Illness (NAMI) for a wide variety of community resources: www.naminycmetro.org. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to view webinars on managing stress, building healthy meals and more: www.1199SEIUBenefits.org/videos. Visit our YouTube Channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents.  Guest Bio  Tiffany Cudjoe-John, MD, is a dedicated psychiatrist with a passion for understanding and addressing the intricate interplay between mind, body and soul. Her journey into psychiatry began after graduating with a degree in chemistry from Johns Hopkins University.   She completed her psychiatric residency at Zucker Hillside Hospital, where she refined her clinical skills and deepened her empathy for individuals facing mental health challenges. Since completing her training in 2009, Dr. Cudjoe-John has dedicated her career to providing compassionate, comprehensive psychiatric care.  For eight years, she practiced Emergency Psychiatry at one of New York City's busiest hospitals, gaining significant experience in crisis intervention, inpatient care and consult-liaison psychiatry. Over the past eight years, she has practiced community mental health at a clinic serving diverse and underserved populations, while also maintaining a private practice.   Dr. Cudjoe-John's approach to care is holistic and patient-centered. She integrates evidence-based psychopharmacology and psychotherapy with personalized treatment plans that honor the individuality of each patient. She strives to create a safe, collaborative environment where patients feel empowered to work toward healing, growth and their fullest potential.  Beyond her clinical work, Dr. Cudjoe-John is passionate about community engagement and mental health advocacy. She has given numerous talks to community groups on mental health awareness and self-care and remains committed to reducing stigma and increasing access to quality mental health care. 

Nervous about speaking in front of your team or at industry events? Seth Dechtman, founder of The Keynote Curators, shares essential public speaking advice from his 20+ years of experience. Learn why preparation beats memorization, how to handle unexpected disruptions, and why your message matters more than your performance. From conquering stage fright to mastering the room without a podium, Seth reveals the techniques that separate amateur presenters from confident communicators. Simplify your business operations: Visit paychex.com/MeetPaychex to learn how Paychex can handle your HR and payroll so you can focus on what counts. Have a topic idea? Share it at https://payx.me/thrivetopics Topics include: 00:00 – Episode preview and guest introduction 02:03 – What is The Keynote Curators? 05:49 – How the speaking industry has changed 06:52 – Why use a speakers bureau? 09:02 – What it takes to succeed as a speaker 12:45 – Everyday business speaking 15:23 – The power of preparation 18:28 – PowerPoints: Help or hindrance? 19:44 – Advice for speakers 24:00 – Style and stagecraft: Podium vs. movement 25:10 – Wrap up and thank you DISCLAIMER: The information presented in this podcast, and that is further provided by the presenter, should not be considered legal or accounting advice, and should not substitute for legal, accounting, or other professional advice in which the facts and circumstances may warrant. We encourage you to consult legal counsel as it pertains to your own unique situation(s) and/or with any specific legal questions you may have.

"I believe that this nation should commit itself to achieving the goal, before this decade is out, of landing a man on the Moon and returning him safely to the Earth." That was President John Kennedy in 1961, speaking at the Joint Session of Congress. It is possibly the best example of a project statement ever made.  Links: Email Me | Twitter | Facebook | Website | Linkedin Join the Time And Life Mastery Programme here. Use the coupon code: codisgreat to get 50% off. Get Your Copy Of Your Time, Your Way: Time Well Managed, Life Well Lived The Time Sector System 5th Year Anniversary The Working With… Weekly Newsletter Carl Pullein Learning Centre Carl's YouTube Channel Carl Pullein Coaching Programmes Subscribe to my Substack  The Working With… Podcast Previous episodes page Script | 397 Hello, and welcome to episode 397 of the Your Time, Your Way Podcast. A podcast to answer all your questions about productivity, time management, self-development, and goal planning. My name is Carl Pullein, and I am your host of this show.  Starting projects. It can be tough. Where do you start? Where will you find the time? And what do you need to do?  These are just some of the questions you will find yourself asking.  Yet the biggest obstacle to completing a project on time is overthinking and over-planning. Thinking about and planning a project are not the same as working on one. Working on a project is doing something that moves it forward.  Decorating your bedroom will require paint and brushes. The only pre-project decision you need to make is what colour.  The first two steps, therefore, are:  Decide what colour to paint the bedroom Buy paint and brushes I would add a third decision: when. When will you do it?  Once you've done those three things, you're ready to go—no more planning, no more thinking. Just get on and start.  Yet, that's not how most projects go, is it? There's thinking, planning, then creating tasks in your task manager, and if it's a work project, a meeting, then perhaps another meeting.  Often, by the time a project is conceived, 80% of the time required to complete it gets spent on thinking, planning, and meetings.  And that brings us nicely to this week's question—a question about finding ways to reduce the thinking and planning time.  So, let me now hand you over to the Mystery Podcast voice for this week's question. This week's question comes from Phil. Phil asks, “Hi Carl, how do you work on complex projects?” I find I spend a lot of time planning a project, end up with a long list of things to do, and when it comes to starting, I freeze. It's as if I don't know where to start. Do you have any tips on handling this type of problem? Hi Phil, thank you for your question.  “Project freeze” is a common problem for many people. I suspect this stems from the belief that every aspect of a project needs to be planned before starting. Yet, for many projects, this would be impossible.  Imagine you were part of NASA in May 1961, and you'd just heard President Kennedy's speech at the joint session of Congress about why the US should put a man on the moon and bring him back safely to earth before the end of the decade.  At that time, NASA was struggling to get even the smallest of rockets into space—the idea of sending astronauts to the moon and back was a pipe dream.  Yet a group of incredible people at NASA in 1961 took on the challenge. Instead of planning every single step they thought would be needed to complete the project, they looked at what they already knew, the obstacles they would need to overcome, and the first steps. That gave birth to the Mercury space mission. The Mercury programme was not to put a man on the moon; its objectives were to orbit a crewed spacecraft around Earth, study the human ability to function in space, and ensure the safe recovery of both the astronaut and the spacecraft. Before they could reach the moon, they needed to understand how humans cope in space. So the project's objective was to send a man into Earth's orbit.  The key was to get started, and they did this by listing out the obstacles they needed to overcome first. They then worked out how to remove those obstacles.  Now, I know our projects are unlikely to be as big as sending someone to the moon and back, but we can adopt the same approach that NASA used to work on our projects.  Even small projects can adopt this approach. Let's say you were asked to do a presentation on the likely effects of AI on your company's business over the next five years. Where would you start?  For something like this, there would be several phases.  The first would be to research and gather information. For this, the task would likely be to find out who to ask or what to read.  Okay, when will you do this?  Here's the key point. It's no good just deciding what needs to be done first. You need to make it intentional, and to do that, you will need to set aside time to do it.  Perhaps you decide to give yourself an afternoon to research this.  Research is a challenge in itself. We can go down rabbit holes that bring no meaningful insights into what we are trying to do. Yet, we can also underestimate how much time is required for research. So the first step is to do an initial session of research to help you develop some boundaries.  You might be lucky and find that the first research session gives you everything you need to start the presentation. However, if not, and you discover you need to do more research, then when will you do that?  One thing you can do with creating a presentation is to set up your PowerPoint or Keynote file. Create the document, do the first slide and perhaps set the theme colours.  Having a document started makes it much easier to get into creating the presentation.  The danger of listing out all the things you think you need to do to complete the project is that 80% of what you think needs to be done doesn't, and you will find that 80% of what ends up being done were things you never thought of in the first place.  All you really need is a starting point.  I recently did a video on how to write a book. The number one reason people who want to write but never do write a book is that they overthink and plan it.  Thinking and planning do not produce a book.  The best way to write a book is to get the first draft written as fast as you can. All that is required is a few ideas about what you want to write about. From there, you start writing the first draft.  The first draft will be the worst state your book will ever be in. It's meant to be messy, unstructured and occasionally unreadable.  But, once you have a first draft, you have around 80,000 words you can manipulate, craft and organise into a best seller. Without that first draft, you have nothing but a few ideas. How do you write a first draft? Set aside time each day to write. An hour or two every day for eight weeks will give you your first draft.  As you write, new ideas will form, and you can make a note of those along the way. That will make your editing easier.  The common denominator with any project is to get started. Everything has a starting point. Wherever that is, start there.  It's as you are working on the project that your next steps reveal themselves.  When I first began creating online courses, I had no idea what I was doing. But what I did have was fifteen years of teaching experience, and I knew how to create a lesson plan.  I also knew what I wanted to create an online course on. So I could create a lesson plan and a topic. That was where I started.  Once I had a lesson plan, I realised I needed a storyboard of sorts to help me break the course down into lessons. That evolved into the outline I have written for every course I have created since.  Now, after eight years of creating courses, I have a process I follow. All I need is a topic and time to plan, outline, record, edit and post. (Five steps)  On big projects, many tasks are completed before the project ends. Yet, if you were to try to predict what needs to be done at the start, you will find you are wasting a lot of time.  NASA had no idea whether a human being could survive in space. What they did know was that they needed to develop a reliable rocket to get them into space. So, they began with that. Without the rocket, it didn't matter whether a human could survive in space or not. There would have been no way of getting them there.  In 1962, NASA didn't know that they would need software to keep the spacecraft on the right trajectory. There was no way they could have planned for that at that point. It was only when they began working on the Gemini programme that they realised software would be needed.  Without paint and brushes, it wouldn't matter what colour you wanted to paint your bedroom.  In many ways, when you're working on a large, complex project, you're solving problems as you go along. Yet, there's always going to be a starting point.  Another thing about bigger projects is setting a deadline.  Because we are not sure how long a large project will take to complete, it can be tempting to set an unrealistic deadline. Three months to complete a project that realistically would take twelve. This is why setting up the project's stages will help you.  What's the first stage? Give yourself a realistic time frame to complete that first stage. The information you gather during that first stage will guide you with the deadlines for the next stage.  I would also take another leaf from NASA's book. President Kennedy said, “before the decade is out”. Given that he made this speech in 1961, NASA had around 9 years to complete the project. Yet it was not absolute.  Theoretically, the deadline was 31 December 1969, but the actual deadline was a grey area until NASA got closer to achieving the goal.  Deadlines are good as they bring energy to the project. Yet, unrealistic deadlines bring nothing but stress to a project.  I know an online course will take me about 6 weeks to complete. I know the process, and I've learned from experience that the whole process takes six weeks.  If I were to stop doing all my other work, close my calendar to appointments and work solidly for fourteen hours a day for two weeks, I might be able to complete the course in two weeks, but all I would have is a lot of stress. Not pleasant.  Six weeks gives me time to bring the course to life, check things, and make sure everything fits together.  And the final part of developing any project is to be clear about your outcomes.  I refer you back to the opening quotation from President Kennedy: "I believe that this nation should commit itself to achieving the goal, before this decade is out, of landing a man on the Moon and returning him safely to the Earth." A perfect project outcome statement. It's clear about the objective, and there is a timeline. There was nothing else for NASA to know. President Kennedy didn't have the skills or knowledge to do this himself; that was for the scientists and engineers to work out.  Something they did with magnificent effort on the 20th July 1969.  Thank you, Phil, for your question and thank you to you, too, for listening. It just remains for me to wish you all a very, very productive week.   

The 2025 International Mars Society Convention convened at the University of Southern California this October for three days of passionate discussion about humanity’s future on the red planet. Speakers explored science, policy, technology, AI, synthetic biology, and the long-term path toward becoming a multi-planet species. In this episode, Mat Kaplan, senior communications adviser at The Planetary Society, shares his conversations with speakers and guests at the Convention. We hear from Robert Zubrin, founder of The Mars Society, who delivered a fiery call to protect NASA’s science programs in the face of unprecedented budget cuts. Humphrey “Hoppy” Price, Chief Engineer for NASA’s Robotic Mars Exploration Program at the Jet Propulsion Laboratory, updates us on the future of Mars Sample Return and new mission architectures. Keynote speaker Dex Hunter-Torricke, a longtime communications leader for SpaceX, Meta, and other major tech organizations, reflects on AI’s promise and peril, and why Mars remains a beacon of hope for humanity’s future. Biologist and technologist Tiffany Vora, vice president for innovation partnerships at Explore Mars, and Erika DeBenedictis, biologist and founder of Pioneer Labs, reveal breakthroughs in synthetic biology and engineered microbes that could help future Martians survive. Steve Benner, chemist and founder of the Foundation for Applied Molecular Evolution (FfAME), revisits the Viking lander experiments and makes a provocative case that we may have found Martian life nearly 50 years ago. Architect Melodie Yashar, CEO of AENARA and a pioneer in 3D-printed habitat research, shares progress in additive construction on Earth and Mars. James Burk, executive director of The Mars Society, discusses advocacy, analog research stations, and the organization’s expanding international footprint. Finally, we meet Sasha, a 13-year-old presenter whose enthusiasm offers a bright glimpse of the next generation of explorers. We wrap up the show with What’s Up with Bruce Betts, chief scientist at The Planetary Society, with a discussion of perchlorates in the Martian soil. Discover more at: https://www.planetary.org/planetary-radio/2025-mars-society-conventionSee omnystudio.com/listener for privacy information.

In this keynote, Ryan Hammett, Director of Market Intelligence & Insights at C.H. Robinson joins us to dive into 2025 surprises from spot rate volatility to shipper psychology. We also dive into the year ahead and look at important trends like US-Mexico trade, macroeconomic moves, and how to sift freight signal from the peak season noise. Keep up with Live FreightWaves Events Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

I heard from so many of you after my first conversation with today's guest that I asked him to come back and take our conversation to the next level.   Who is this mystery guest? Well, today, on Notable Leaders' Radio, I speak with Chad Lefevre, Founder and Ceo of The Most Important Conversations. He highlights how embracing your unique wiring as a creator can transform uncertainty into opportunity and inspire you to step into your own leadership and impact. In today's episode, we discuss: Discover Your Early Sparks. Ever wonder why some kids just don't stop asking "why?" Chad did that to the point of driving his mom nuts. So it was no surprise that, in Catholic school, the traditions and rituals drew him toward life's deeper mysteries. That kid-like curiosity? It's your clue to passions waiting to light up your path, no matter your age now.​   Own Your Unique Wiring. Notice where you think differently, ask endless questions, or spot connections others miss. Chad calls this your natural wiring, not a glitch, and says leaning into it turns "annoying" traits into your secret edge for fresh ideas. We've all got that inner wiring; the question is, are you plugging it in?   Master the Pause in Chaos. That urge to react when life hits hard? Chad's emotional sobriety trick, feel it, breathe, saved him from recycling stress loops. In our wild world of AI shake-ups and uncertainty, this space between trigger and response is your superpower for calm, smart moves.   Step Up in the Storm. With jobs shifting and change everywhere, do your best not to freeze like you are watching a car wreck. Chad challenges us: who will you become amid it all, a fighter, fleer, or creator, grabbing the opportunity? Link arms in community, trust your gut, and turn disruption into your breakthrough story.   RESOURCES: Complementary Resources: …https://www.inc.com/tracy-leigh-hazzard/building-fans-by-connecting-brands-to-brains.html  Guest Bio: Chad Lefevre is an international Design Thinker, business philosopher and strategist, author, speaker and psychonaught with twenty years of senior business experience, successfully designing business strategy, and leading cultural transformation and leadership development initiatives from start-ups to Fortune 100 companies.  Chad's work centers around Liberation, creativity, and being-centered human potential. He focuses on designing and delivering on what is possible when human beings are liberated, in alignment, empowered, and supported to overcome limiting perceptions and beliefs, to increase performance and deliver desired outcomes for themselves and the companies they work for.  Chad is Founder and CEO of The Most Important Conversations (TMIC) a ground-breaking weekly online transformation community, which some have referred to as "AA for healthy normals". Previously, he was Founder of NeuroBe Inc., a research and consulting firm focused on delivering profound performance inside of corporations by working with leaders in the areas of being, perception, and cognitive mastery. He was also co-Founder of Ncite Neuromedia, a neuroscience-based video game development company specializing in leadership development through what he referred to as "transformational gaming".  Chad has has architected transformative business strategies and solutions effecting the areas of business operations, leadership development, cultural transformation and team building, branding, PR and marketing communications (for which he was featured in INC.). His work has included serving such companies/brands as: Coca-Cola, TELUS, Sony Music Latin, Music World, SimWin (AI sports leagues), United Way, Shell, Hoffman, the Canfield Group, Bell, Richard Blanco: Poet Laureate to the Obama Administration; co-producing SANG (which featured leading thinkers including Tony Robbins, Jack Canfield, Peter Guber, Tony Hsieh, and Peter Diamandis, among hundreds of others); co-producing the Sundance Thought Leader Summit, participating in Larry King's Breakfast Club, among others. Chad is an avid student and researcher in the areas of neuropsychology, perception, and choice making. Other areas of research and expertise supporting his work include game theory, complexity theory, change management, and Systems Thinking.  Website/Social Links …  https://chadlefevre.com The Most Important Conversations @ https://tmicglobal.com https://tmicglobal.com  https://www.linkedin.com/in/chadlefevre /   Belinda's Bio: Belinda is a sought-after Leadership Advisor, Coach, Consultant and Keynote speaker and a leading authority in guiding global executives, professionals and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with such organizations as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has delivered more than 72 interviews with top-level executives and business leaders who share their inner journey to success; letting you know the truth of what it took to achieve their success in her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President, Global Director of Creative Management at Grey Advertising, managing 500 people around the globe. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace. Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/

Back on stage at the 4th annual MADabolic Franchise Conference this year with a presentation about productivity and tactical ways to audit your day to extract the bullshit and get more done. —-------------------------------------------------------------------------------------------------------------I solve problems in your business and make you more money.  Guaranteed. For over a decade I've been working with gym owners (via one-on-one consulting) to help create tailored solutions to solve their business problems, engineer the game plan and empower them to execute the strategy.Stop wishing your business problems are going to magically go away.  Invest in your business and let me solve your problems and optimize your business fast and efficiently. We'll work together daily/weekly, with a monthly call until the problem is solved and then I want you to fire me.  Because this is YOUR business, I'm just here to solve a specific problem and then get out of your way.⁠Learn more about what it's like for us to work together.⁠—-------------------------------------------------------------------------------------------------------------Want to increase your business IQ by 100x for only $50? Get enrolled in Microgym University - the only online business school that teaches you the best practices and business frameworks from some of the most successful brands in our industry and then lets you decide which ones to install in your business.New courses are added every month. ⁠⁠www.microgymuniversity.com⁠⁠ —-------------------------------------------------------------------------------------------------------------Need help leasing or buying a building?I created the Gym Real Estate Company so that gym owners had someone who could go beyond the duties of a typical real estate broker and actually advise them on business aspects as they relate to site selection, market location fit, operational capacity, facility layout, pre-sell marketing, and more.If you're looking for help with your next lease or if you want us to help you along the journey of buying a building -⁠ ⁠⁠⁠head over to www.gymrealestate.co and book a Discovery Call.⁠—--------------------------------------------------------------------------------------------------------------

Missed Rally Live #10? No worries! In this special episode, we're bringing you the powerful Rally Live #10 keynote from Sarah Herron—reality TV alum, writer, advocate, and founder of SheLift. While many of you first met Sarah on The Bachelor, her true impact has come from the way she's chosen to tell her own infertility story: with honesty, vulnerability, humor, and a fierce commitment to helping others feel less alone. In her keynote, Sarah opens up about living with a limb difference, navigating infertility, experiencing profound pregnancy loss, and redefining resilience on her own terms. She speaks candidly about grief, identity, mental health, and the unexpected places strength can be found. Her words remind us that we can hold joy and heartbreak at the same time—and that there is power in embracing our imperfections. She also talks about being a twin mom and a "Forever mom" to her sweet son, Oliver, who she honors every day. Follow Sarah on IG: @sarahherronEPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.Order "Work of ART," "Beautiful Bird" and "You Are a Work of ART," now at https://www.infertileafgroup.com/booksFERTILITY RALLYIG: @fertilityrallywww.fertilityrally.comNo one should go through infertility alone. Join the Worst Club with the Best Members at fertilityrally.com. We offer 5 to 6 support groups per week, three private Facebook groups, tons of curated IRL and virtual events, and an entire community of more than 500 women available to support you, no matter where you are in your journey.Join today at link in bio on IG @fertilityrally or at www.fertilityrally.com/membershipPHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com. Go to PherDal.com today and use code INFERTILEAF for $10 off. Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Simon and Jillian catch you up on the highlights from today's keynote PLUS all the "pre:Invent" announcements that took place prior to the event!